“派罗欣”治疗乙肝病毒疗效比常规干扰素高一倍

　　新华社信息北京4月10日电 亚洲网悉尼消息，在澳大利亚悉尼召开的第11届病毒性肝炎和肝脏疾病国际研讨会上公布的研究结果显示，新一代丙型肝炎治疗药物“派罗欣”(pEGASYS)要比治疗慢性乙型肝炎(CHB)的常规干扰素的疗效高一倍以上。

　　在服用6个月的“派罗欣”，采用与治疗丙型肝炎时一样的180微克的剂量后，有28%的患者出现乙型肝炎e抗原(HBeAg)丧失､乙型肝炎病毒脱氧核糖核酸低于50万复件/毫升以及ALT正常化的综合结果，而使用常规干扰素的患者中只有12%。

　　目前，拉米夫定和常规干扰素alfa是获准用于治疗乙型肝炎的唯一药剂。但这些药剂就整体疗效而言都有明显的局限性，使用拉米夫定的患者中约有20%的人会在治疗一年内对药物产生抗药性，而且大多数患者需要无限期地继续治疗。“派罗欣”能在确定疗程内提供更高的疗效，而且乙型肝炎病毒不太可能对“派罗欣”产生抗药性。

　　乙型肝炎是血液中的一种病毒，它损害人的肝脏，是世界上最常见的严重的肝脏传染病。乙型肝炎病毒具有高度传染性，是人体免疫缺损病毒(HIV)的100倍。

　　“派罗欣”是治疗丙型肝炎的新一代药物，为所有受基因型丙肝病毒感染的患者提供优于常规干扰素疗法的显著疗效。“派罗欣”能提供持续的病毒抑制，比常规干扰素能更优先地分配到肝脏。“派罗欣”已在70多个国家和地区获准用于治疗慢性丙型肝炎。

　　罗氏公司致力于开发病毒性肝炎的治疗办法，已经推出治疗乙型和丙型肝炎的“力度伸-A”，后又推出治疗丙肝的“派罗欣”。罗氏公司还制造乙型肝炎病毒和丙型肝炎病毒诊断与监测系统。

　　以下来自基因潮网站：

　　罗氏：Pegasys能显著促进乙肝治疗

　　瑞士制药巨头罗氏（Roche）4月9日表示研究证明该公司的抗丙肝药物Pegasys能有效促进乙肝的治疗。

SYDNEY -(Dow Jones)- Swiss pharmaceutical company Roche Holding AG said Wednesday a new study found that its hepatitis C drug Pegasys also more than doubled the efficacy of conventional treatments of chronic hepatitis B.

Study results presented April 9 at the 11th International Symposium on Viral Hepatitis and Liver Disease, in Sydney demonstrate that PEGASYS, a new generation hepatitis C therapy, more than doubled the efficacy of conventional interferon in the treatment of chronic hepatitis B (CHB).

The Phase II study assessed the efficacy of PEGASYS in patients with difficult-to-treat HBeAg-positive CHB, which was defined as high pre-treatment HBV DNA (high levels of replicating virus in the patient's liver) and low pre- treatment ALT (indicating a weak natural response from the patients immune system to HBV).

These factors are considered predictors of a poor response to HBV therapy. As in hepatitis C, where genotype 1 is considered difficult to treat, there is also evidence that those infected by the HBV genotype C virus respond less well to treatment.

"Until now, there was only a slim chance that these hepatitis B patients could be cured of their disease," said Professor Graham Cooksley, the lead investigator of the study and Senior Principal Research Fellow, Clinical Research Centre, Royal Brisbane Hospital, Australia.

"These monotherapy results are extremely positive and demonstrate the same kind of efficacy in hepatitis B as we saw with genotype 1 patients in hepatitis C. PEGASYS works very well in those with the most treatment-resistant disease."

Company Web Site: http://www.roche.com